🔴 GRAIL is trading 8.67% down today after adjusted EBITDA losses widened

GRAIL is trading 8.67% down now at $67.75 after investors focused on widening adjusted EBITDA losses following its August 5, 2026 earnings release.

• Second-quarter revenue reached $44.7 million; Galleri volume rose 35% to more than 61,000 tests.
• Adjusted EBITDA losses widened to $90.3 million, while net loss remained $110.2 million.
• Investors also weighed the uncertain FDA approval timeline, including a potential fall advisory committee; shares closed August 5 at $74.18, up 2.04%, before an after-hours selloff.